Please assess the completion status of the following clinical trial:

Trial Title: First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female subjects between 18 and 75years of age, inclusive~* Diagnosis of Pompe disease~Enzyme Replacement Therapy (ERT)-experienced subject (ambulatory):~* Has received ERT with alglucosidase alfa for the previous 2-6 years, inclusive~* Subject is currently receiving alglucosidase alfa (Myozyme/Lumizyme), at a frequency of once every other week~* Must be able to walk 200-500 meters on the 6-Minute Walk Test (6MWT )~* Has upright Forced Vial Capacity (FVC) 30% to 80% of predicted normal value~ERT-experienced subjects (non-ambulatory):~* Has received ERT with alglucosidase alfa (Myozyme/Lumizyme) for ≥2 years~* Is wheelchair-bound~ERT-naïve subjects (ambulatory):~* Must be able to walk 200-500 meters on the 6MWT~* Has upright FVC must be 30% to 80% of predicted normal value~* Subject has never received alglucosidase alfa~Enzyme Replacement Therapy (ERT)-experienced subject (ambulatory):~* Has received ERT with alglucosidase alfa for \>7years, inclusive~* Subject is currently receiving alglucosidase alfa (Myozyme/Lumizyme), at a frequency of once every other week~* Must be able to walk 200-500 meters on the 6-Minute Walk Test (6MWT )~* Has upright Forced Vial Capacity (FVC) 30% to 80% of predicted normal value~Exclusion Criteria:~* Subject has received treatment with prohibited medications within 30 days of Baseline Visit~* Subject, if female, is pregnant or breastfeeding at screening~* Subject, whether male or female, planning to conceive a child during the study~* Subject has a medical or any other extenuating condition or circumstance that may, in opinion of investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements~* Subject has a history of allergy or sensitivity to miglustat or other iminosugars~* Subjects with active systemic autoimmune disease such as lupus, scleroderma, or rheumatoid arthritis. All subjects with autoimmune disease must be discussed with the Amicus Medical Monitor~* Subjects with active bronchial asthma. All subjects with bronchial asthma must be discussed with the Amicus Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ATB200 (Type: EXPERIMENTAL): In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200 for 3 dosing periods.
- ATB200 + AT2221 (Type: EXPERIMENTAL): In Stage 2, safety, tolerability, and PK will be evaluated following single- and multiple-ascending dose combinations of ATB200 co-administered with AT2221 (Miglustat) In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)

Based on this trial design, predict the completion outcome and termination type (if applicable).